8-K: Viking Therapeutics Announces Positive Q1 2024 Results and Clinical Pipeline Update

Viking Therapeutics reported positive results from its Phase 2 VENTURE trial for VK2735, a dual GLP-1/GIP agonist, and completed a $630 million public offering.

Summary

• Viking Therapeutics announced its financial results for the first quarter of 2024, highlighting significant progress in its clinical programs.
• The company reported positive topline results from the Phase 2 VENTURE study of subcutaneous VK2735 in obesity, showing up to 13.1% placebo-adjusted weight loss at 13 weeks.
• Initial data from a Phase 1 study of oral VK2735 demonstrated up to 3.3% placebo-adjusted weight loss after 28 days.
• Viking completed the 52-week biopsies for the Phase 2b VOYAGE study of VK2809 in NASH and fibrosis, with results expected later in the second quarter of 2024.
• The company successfully completed a public offering of common stock, raising approximately $630 million in gross proceeds.
• Viking's cash position at the end of the quarter was $963 million.
• Research and development expenses increased to $24.1 million for the quarter, compared to $11.0 million in the same period of 2023.
• The company reported a net loss of $27.4 million, or $0.26 per share, for the quarter.

Sentiment

Score: 9

Explanation: The document is highly positive due to the strong clinical results, successful capital raise, and clear path forward for multiple programs. The company's financial position is also very strong.

Positives

• The Phase 2 VENTURE trial of VK2735 achieved its primary and secondary endpoints, demonstrating significant weight loss.
• The oral formulation of VK2735 showed promising early results in a Phase 1 trial, with good safety and tolerability.
• The VOYAGE study of VK2809 achieved its primary endpoint, showing significant reductions in liver fat.
• Viking's strong cash position of $963 million provides financial flexibility for further development.
• The company plans to meet with regulators to discuss the path forward for VK2735.
• VK2809 demonstrated comparable liver fat reductions in patients with and without type 2 diabetes.
• VK2809 showed excellent GI tolerability in the VOYAGE study.

Negatives

• The company reported a net loss of $27.4 million for the first quarter of 2024.
• Research and development expenses increased significantly to $24.1 million for the quarter.
• General and administrative expenses also increased to $10.0 million for the quarter.

Risks

• The success of clinical trials is not guaranteed, and prior results may not be replicated.
• Regulatory approvals are subject to risks and uncertainties.
• The company's financial performance is dependent on the success of its clinical programs.
• There are risks associated with the cost and timing of product development activities.
• The company is subject to risks related to competition in the biopharmaceutical industry.

Future Outlook

Viking plans to meet with regulators to discuss the path forward for both subcutaneous and oral VK2735 programs and expects to advance each program into further development later this year. The company also anticipates reporting 52-week histology results from the VOYAGE study in the second quarter of 2024 and results from the Phase 1b study of VK0214 in mid-2024.

Management Comments

• The first quarter of 2024 was an exceptional period for Viking, stated Brian Lian, Ph.D., chief executive officer of Viking.
• We plan to meet with regulators to discuss the path forward for both programs, and expect to advance each program into further development later this year.
• These funds will support the ongoing advancement of Viking's pipeline through important clinical milestones.

Industry Context

This announcement is significant in the context of the competitive landscape for obesity and NASH treatments. The positive results for VK2735, a dual GLP-1/GIP agonist, position Viking as a potential competitor to other companies developing similar therapies. The progress of VK2809 in NASH also places Viking in a competitive position in the liver disease space.

Comparison to Industry Standards

• The 13.1% placebo-adjusted weight loss for subcutaneous VK2735 at 13 weeks is competitive with other GLP-1 based therapies such as those from Eli Lilly (Tirzepatide) and Novo Nordisk (Semaglutide).
• The 3.3% placebo-adjusted weight loss for oral VK2735 at 28 days is promising for an oral formulation, though further data is needed to compare to oral competitors.
• The liver fat reductions observed with VK2809 are comparable to other NASH therapies in development, such as those from Madrigal Pharmaceuticals (Resmetirom).
• The safety and tolerability profiles of both VK2735 and VK2809 appear favorable compared to some competitors, particularly in terms of GI side effects.

Stakeholder Impact

• Shareholders will benefit from the positive clinical results and the company's strong financial position.
• Employees will be impacted by the company's growth and development.
• Patients may benefit from the development of new therapies for obesity, NASH, and X-ALD.
• Creditors will be impacted by the company's strong cash position.

Next Steps

• Viking plans to meet with the FDA to discuss the next steps in the development of VK2735.
• The company plans to advance both subcutaneous and oral VK2735 programs into further development later this year.
• Viking expects to report 52-week histology results from the VOYAGE study in the second quarter of 2024.
• The company expects to announce results from the Phase 1b study of VK0214 in mid-2024.
• Viking plans to initiate a Phase 2 trial of oral VK2735 in patients with obesity later this year.

Key Dates

Keywords

VK2735, VK2809, Obesity, NASH, GLP-1, GIP, Thyroid Hormone Receptor Agonist, Weight Loss, Liver Fat, Clinical Trial, Biopharmaceutical, Metabolic Disorders, X-ALD, VK0214